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“The Quest for the Perfect Prostate Biopsy Continues" 
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Until well into the 1980's, biopsy of the prostate often relied on a few cores using 
a device such as the Vim-Silverman needle digitally guided either trans-
perineally or transrectally into a palpably abnormal prostate. In this pre-PSA era, 
prostate cancers were often detected at an advanced clinical stage. The 
modern era of prostate biopsy was ushered in the late 1980's with the 
development of the spring loaded biopsy needle and the trans-rectal 
ultrasound (TRUS) probe. Since that time, the state of the art has evolved from 
the TRUS directed biopsy of suspicious lesions, to the sextant and now extended 
10-12 core biopsy schema using local anesthesia. The decision to perform 
prostate biopsy today is often based on the interpretation of changes in serum 
PSA, leading to cancer detection in palpably normal prostate glands. 
 
Our current "gold standard" prostate biopsy is based on standard gray scale 
TRUS imaging. Although early investigations suggested that prostate cancer is 
seen as a "hypoechoic lesion" on TRUS, the reality today is that most PSA 
detected cancers have a highly variable appearance. These cancers do not 
demonstrate any unique characteristics on gray scale imaging. While a 
sonographically distinct lesion is biopsied when seen, distinguishing benign from 
malignant tissue with standard ultrasound is challenging. (1) Standard gray scale 
TRUS is very effective at providing an accurate size determination as well as 
guiding the biopsy needle ensuring an adequate sampling of the various 
regions of the gland. It usually falls short in the detection of all prostate cancers 
that may be present due to the common small and multifocal nature of the 
disease. 
 
Changes in the management of prostate cancer require a much more careful 
assessment of the prostate cancer than ever. No longer is it appropriate to 
identify simply the largest or index tumor and make a simple diagnosis of 
prostate cancer. Standard and evolving approaches, such as active 
surveillance and focal therapy, ideally require that all lesions within the prostate 
be detected and characterized to determine the appropriate course of action. 
Multifocality is the rule rather than the exception and identifying the tumor with 
the aggressive phenotype can no longer be made based on size alone. Using a 
saturation biopsy approach with 20 or more cores, may not be appropriate for 
the initial biopsy but has utility in the repeat biopsy setting. (2) 
 
Many imaging technologies have been studied to improve the biopsy yield. 
Color Doppler ultrasound enhanced prostate biopsy has limitations but when 
combined with microbubble contrast agents, improvements are seen. Work at 
our Jefferson Prostate Diagnostic center and by others has demonstrated that 
hypervascular prostate cancers can be detected with fewer biopsy cores using 
microbubble contrast-enhanced ultrasound (CEUS). Most significantly, cancers 
with higher Gleason grades cancers are more likely to be detected with CEUS 
when compared to other TRUS approaches. (1,3) Even with this improvement in 
the detection of higher grade cancers, systematic biopsies are still required with 
these techniques to optimize the detection of prostate cancer. Several papers 
in this issue of the Journal of Urology address prostate biopsy and tumor 
detection. 
 
Elastography, also known as elastosonography, represents a newer TRUS based 
technique that relies on alterations in tissue stiffness that may indicate the 
presence of prostate cancer. In our Jefferson Prostate Diagnostic Center's initial 
elastography experience, areas identified in the prostate with an abnormal 
elastography pattern were twice as likely to be prostate cancer when 
compared to biopsies in areas of normal elasticity. (4) Using real time 
elastography, Brock and associates also noted a higher biopsy yield, but in 
similar fashion to the CEUS experience previously cited, it was not sensitive 
enough to omit the systematic biopsies. (5)   
 
MRI has enjoyed a significant growth in the management of prostate cancer 
with improvements in the multi parametric MRI such as higher power scanners 
and newer imaging protocols. Although very cumbersome, MRI directed 
biopsies are performed at selected centers. In spite of the enthusiasm for more 
complete detection of all prostate lesions by MRI, Rosenkrantz and associates 
note that many tumors are not detected by these MRI techniques and suggest 
the further study of the missed tumors be used to improve MRI imaging (6). 
Fusion of MRI with TRUS imaging and biopsy is a promising approach to gain the 
benefits of both technologies. (7)   
 
A potential advantage of MRI is in the identification of anteriorly located tumors 
that may escape a transrectal needle biopsy approach. Huo and associates 
report on their experience with initial transperineal template biopsy. (8) The 
transperineal approach potentially allows a more complete biopsy of the 
prostate including the anterior zone.  They note only a fair pathologic 
agreement with the final radical prostatectomy specimens and suggest larger 
prostates require more biopsies using this approach.  
 
While the short term risks of prostate biopsy are well known, little data is available 
on the long term implications of repeat transrectal biopsy on cancer outcomes. 
It is reassuring that in the era of active surveillance with mandated repeat 
prostate biopsies, in a cohort analysis of over 2700 men in the SEARCH database 
a repeat prostate biopsy did not demonstrate an increased risk of biochemical 
recurrence following radical prostatectomy. (9)  
 
Our current biopsy methods adequately identify larger non-palpable lesions. As 
we move to earlier detection of prostate cancer, the lesions become smaller 
and more difficult to detect by our standard biopsy and imaging techniques. 
Some argue that these smaller lesions are clinically insignificant and of no 
clinical consequence. This adds fuel to the ongoing prostate cancer screening 
controversy by causing detection and overtreatment of small cancers that will 
never harm the patient. (10)  However, these smaller lesions may exhibit 
characteristics of clinically aggressive disease regardless of size and may impact 
treatment decisions particularly in men with long life expectancies. In our quest 
for the perfect prostate biopsy, identifying lesions by needle biopsy or imaging 
may not be enough. Methods to more precisely discriminate aggressive 
prostate cancer from indolent disease should also be a part of our biopsy efforts 
going forward.   
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